NF-κB/Rel-mediated regulation of apoptosis in hematologic malignancies and normal hematopoietic progenitors

Leukemia

Volumn 18, Issue 1, 2004, Pages 11-17

  Turco, M C ^a,b   Romano, M F ^a   Petrella, A ^a   Bisogni, R ^a   Tassone, P ^a   Venuta, S ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF SALERNO   (Italy)

Author keywords

Apoptosis; Hematologic neoplasias; NF B Rel; Progenitors

Indexed keywords

CARRIER PROTEIN; CASPASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BCL 2; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR REL;

APOPTOSIS; CELL SURVIVAL; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; GENE REARRANGEMENT; GENE TARGETING; GENETIC REGULATION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL; IMMUNE SYSTEM; MOLECULAR CLONING; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; BLOOD DISEASE; DRUG EFFECT; HUMAN; PATHOLOGY; PHYSIOLOGY;

ANIMALS; APOPTOSIS; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELLS; HUMANS; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-REL; SIGNAL TRANSDUCTION;

EID: 0742324492     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403171     Document Type: Review

References (104)

1. Ghosh S, May MJ, Kopp EB. NF-κB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998; 16: 225-260.
2. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu Rev Immunol 2000; 18: 621-623.
3. Rothwarf DM, Karin M. The NF-κB activation pathway: a paradigm in information transfer from membrane to nucleus. Sci STKE 1999; 5: RE1.
4. Herr I, Debatin K-M. Cellular stress response and apoptosis in cancer therapy. Blood 2001; 89: 2603-2614.
5. Rayet B, Gèlinas C. Aberrant rel/nfκb genes and activity in human cancer. Oncogene 1999; 18: 6938-6947.
6. Beg AA, Baltimore D. An essential role of NF-κB in preventing TNF-κ-induced cell death. Science 1996; 274: 782-784.
7. Liu Z-G, Hsu H, Goeddel DV, Garin M. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-KB activation prevents cell death. Cell 1996; 87: 565-576.
8. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM. Suppression of TNF-κ-induced apoptosis by NF-κB. Science 1996; 274: 787-789.
9. Wang CY, Mayo MW, Baldwin AS. TNF- and cancer therapy induced apoptosis: potentiation by inhibition of NF-κB. Science 1996; 274: 784-787.
10. Wu M, Lee H, Bellas RE, Schauer SL, Arsura M, Katz D et al. Inhibition of NF-κB/Rel induces apoptosis of B cells. EMBO J 1996; 15: 4682-4690.
11. Karin M, Ling A. NF-κB at the crossroads of life and death. Nat Immunol 2002; 3: 221-227.
12. Wang CY, Cusack Jr JC, Liu R, Baldwin Jr AS. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nat Med 1999; 5: 412-417.
13. White MK, McCubrey JA. Suppression of apoptosis: role in cell growth and neoplasia. Leukemia 2001; 15: 1011-1021.
14. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB. J Clin Invest 2001; 107: 241-246.
15. Orlowski RZ, Baldwin AS. NF-κB as a therapeutic target in cancer. Trends Mol Med 2002; 8: 385-390.
16. Mathew S, Murty VV, Dalla-Favera R, Chaganti RS. Chromosomal localization of genes encoding the transcription factors, c-rel, NF-κBp5O, NF-κBp65, and lyt-10 by fluorescence in situ hybridization. Oncogene 1993; 8: 191-193.
17. Chang CC, Zhang J, Lombardi L, Neri A, Dalla-Favera R. Mechanism of expression and role in transcriptional control of the proto-oncogene NFκB-2/LYT-10. Oncogene 1994; 9: 923-933.
18. Migliazza A, Lombardi L, Rocchi M, Trecca D, Chang CC, Antonacci R et al. chromosomal aberrations generate 3′ truncations of the NFκB2/lyt-10 gene in lymphoid malignancies. Blood 1994; 84: 3850-3860.
19. Thakur S, Lin HC, Tseng WT, Kumar S, Bravo R, Foss F et al. Rearrangement and altered expression of the NFκB-2 gene in human cutaneous T-lymphoma cells. Oncogene 1994; 9: 2335-2344.
20. Dobrzanski P, Ryseck RP, Bravo R. Specific inhibition of RelB/p52 transcriptional activity by the C-terminal domain of p100. Oncogene 1995; 10: 1003-1007.
21. Heusch M, Lin L, Geleziunas R, Greene WC. The generation of nfκb2 p52: mechanism and efficiency. Oncogene 1999; 18: 6201-6208.
22. Wang Y, Cui H, Schroering A, Ding JL, Lane WS, McGill G et al. NF-κB2 p100 is a pro-apoptotic protein with anti-oncogenic function. Nat Cell Biol 2002; 4: 888-893.
23. Hacker H, Karin M. Is NF-κB2/p100 a direct activator of programmed cell death? Cancer Cell 2002; 2: 431-433.
24. Brownell E, Fell HP, Tucker PW, Geurts van Kessel AH, Hagemeijer A, Rice NR. Regional localization of the human c-rel locus using translocation chromosome analysis. Oncogene 1988; 2: 527-529.
25. Barth TF, Dohner H, Werner CA, Stilgenbauer S, Schlotter M, Pawlita M et al. Characteristic pattern of chromosomal gains and losses in primary large B-cell lymphomas of the gastrointestinal tract. Blood 1998; 91: 4321-4330.
26. Houldsworth J, Mathew S, Rao PH, Dyomina K, Louie DC, Parsa N et al. REL proto-oncogene is frequently amplified in extranodal diffuse large cell lymphoma. Blood 1996; 87: 25-29.
27. Barth TF, Martin-Subero JI, Joos S, Menz CK, Hasel C, Mechtersheimer G et al. Gains of 2p involving the REL locus correlate with nuclear c-Rel protein accumulation in neoplastic cells of classical Hodgkin lymphoma. Blood 2003; 101: 3681.
28. Capobianco AJ, Simmons DL, Gilmore TD. Cloning and expression of a chicken c-rel cDNA: unlike p59v-rel, p68c-rel is a cytoplasmic protein in chicken embryo fibroblasts. Oncogene 1990; 5: 257-265.
29. Gilmore TD. The Re1/NF-κB/I kappa B signal transduction pathway and cancer. Cancer Treat Res 2003; 115: 241-265.
30. Ohno H, Takimoto G, McKeithan TW. The candidate protooncogene bcl-3 is related to genes implicated in cell lineage determination and cell cycle control. Cell 1990; 23: 991-997.
31. Au WY, Horsman DE, Ohno H, Klasa RJ, Gascoyne RD. Bcl-3/IgH translocation (14;19)(q32;q13) in non-Hodgkin's lymphomas. Leuk Lymphoma 2002; 43: 813-816.
32. Nishikori M, Maesako Y, Ueda C, Kurata M, Uchiyama T, Ohno H. High-level expression of BCL3 differentiates t(2;5)(p23;q35)-positive anaplastic large cell lymphoma from Hodgkin disease. Blood 2003; 101: 2789-2796.
33. Watanabe N, Iwamura I, Shinoda T, Fujita T. Regulation of NFKB1 protein by the candidate oncoprotein BCL-3: generation of NF-κB homodimers from the cytoplasmic pool of p50-p150 and nuclear translocation. EMBO J 1997; 16: 3609-3620.
34. Heissmeyer V, Krappmann D, Wulczyn FG, Scheidereit C. NF-κB p105 is a target of IkappaB kinases and controls signal induction of Bcl-3-p50 complexes. EMBO J 1999; 18: 4766-4778.
35. Michel F, Soler-Lopez M, Petosa C, Cramer P, Siebenlist U, Muller CW. Crystal structure of the ankyrin repeat domain of Bcl-3: a unique member of the IκB protein family. EMBO J 2001; 20: 6180-6190.
36. Dechend R, Hirano F, Lehmann K, Heissmeyer V, Ansieau S, Wulczyn FG et al. The Bcl-3 oncoprotein acts as a bridging factor between NF-κB/Rel and nuclear co-regulators. Oncogene 1999; 18: 3316-3323.
37. Willis TG, Jadayel DM, Du MQ, Peng H, Perry AR, Abdul-Rauf M et al. Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. Cell 1999; 96: 35-45.
38. Zhang Q, Siebert R, Yan M, Hinzmann B, Cui X, Xue L et al. Inactivating mutations and overexpression of BCL10, a caspase recruitment domain-containing gene, in MALT lymphoma with t(1;14)(p22;q32). Nat Genet 1999; 22: 63-68.
39. Guiet C, Vito P. Caspase recruitment domain (CARD)-dependent cytoplasmic filaments mediate bcl10-induced NF-κB activation. J Cell Biol 2000; 148: 1131-1140.
40. Thome M, Tschopp J. Bcl10. Curr Biol 2002; 12: R45.
41. Yui D, Yoneda T, Oono K, Katayama T, Imaizumi K, Tohyama M. Interchangeable binding of Bcl10 to TRAF2 and ciAPs regulates apoptosis signaling. Oncogene 2001; 20: 4317-4323.
42. Ohshima K, Muta H, Kawasaki C, Muta K, Deyev V, Kanda M et al. Bcl10 expression, rearrangement and mutation in MALT lymphoma: correlation with expression of nuclear factor-κB. Int J Oncol 2001; 19: 283-289.
43. Dierlamm J, Baens M, Wlodarska I, Stefanova-Ouzounova M, Hernandez JM, Hossfeld DK et al. The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21-q21) associated with mucosa-associated lymphoid tissue lymhomas. Blood 1999; 93: 3601-3609.
44. Uren AG, O'Rourke K, Aravind LA, Pisabarro MT, Seshagiri S, Koonin EV et al. Identification of paracaspases and metacaspases: two ancient families of caspase-like proteins, one of which plays a key role in MALT lymphoma. Mol Cell 2000; 6: 961-967.
45. Lucas PC, Yonezumi M, Inohara N, McAllister-Lucas LM, Abazeed ME, Chen FF et al. Bcl10 and MALT1, independent targets of chromosomal translocation in MALT lymphoma, cooperate in a novel NF-κB signaling pathway. J Biol Chem 2001; 276: 19012-19019.
46. Ye H, Liu H, Raderer M, Chott A, Ruskone-Fourmestrsux A, Wotherspoon A et al. High incidence of t(11;18)(q21;21) in Helicobacter pylori-negative gastric MALT lymphoma. Blood 2003; 101: 2547-2550.
47. Bargou RC, Emmerich F, Krappmann D, Bommert K, Mapara MY, Arnold W et al. Constitutive nuclear factor-κB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest 1997; 100: 2961-2969.
48. Hinz M, Loser P, Mathas S, Krappmann D, Dorken B, Scheidereit C. Constitutive NF-κB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells. Blood 2001; 97: 2798-2807.
49. Izban KF, Ergin M, Huang Q, Qin JZ, Martinez RL, Schnitzer B et al. Characterization of NF-κB expression in Hodgkin's disease: inhibition of constitutively expressed NF-κB results in spontaneous caspase-independent apoptosis in Hodgkin and Reed-Sternberg cells. Mod Pathol 2001; 14: 297-310.
50. Emmerich F, Meiser M, Hummel M, Demel G, Foss HD, Jundt F et al. Overexpression of IκB alpha without inhibition of NF-κB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells. Blood 1999; 94: 3129-3134.
51. Horie R, Watanabe T, Ito K, Morisita Y, Watanabe M, Ishida T et al. Cytoplasmic aggregation of TRAF2 and TRAF5 proteins in the Hodgkin-Reed-Sternberg cells. Am J Pathol 2002; 160: 1647-1654.
52. Horie R, Watanabe T, Morishita Y, Ito K, Ishida T, Kanegae Y et al. Ligand-independent signaling by overexpressed CD30 drives NF-κB activation in Hodgkin-Reed-Sternberg cells. Oncogene 2002; 21: 2493-2503.
53. Jeang KT. Functional activities of the human T-cell leukemia virus type I Tax oncoprotein: cellular signaling through NF-κB. Cytokine Growth Factor Rev 2001; 12: 207-217.
54. Gu L, Findley HW, Zhou M. MDM2 induces NF-κB/p65 expression transcriptionally through Sp1-binding sites: a novel, p53-independent role of MDM2 in doxorubicin resistance in acute lymphoblastic leukemia. Blood 2002; 99: 3367-3375.
55. Hamdane M, David-Cordonnier MH, D'Halluin JC. Activation of p65 NF-κB protein by p210BCR-ABL in a myeloid cell line (P210BCR-ABL activates p65 NF-kappaB). Oncogene 1997; 15: 2267-2275.
56. Wu WS, Xu ZX, Hittelman WN, Salomoni P, Pandolfi PP, Chang KS. Promyelocytic leukemia protein sensitizes tumor necrosis factor alpha-induced apoptosis by inhibiting the NF-κB survival pathway. J Biol Chem 2003; 278: 12294-12304.
57. Romano MF, Lamberti A, Bisogni R, Tassone P, Pagnini D, Storti G et al. of cytosine arabinoside-induced apoptosis in human myeloblastic leukemia cells by NF-κB/Rel-specific decoy oligodeoxynucleotides. Gene Ther 2000; 7: 1234-1237.
58. Guzman ML, Neering SJ, Upchurch D, Grimes B, Howard DS, Rizzieri DA et al. Nuclear factor-κB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001; 98: 2301-2307.
59. Wuchter C, Krappmann D, Cai Z, Ruppert V, Scheidereit C, Dorken B et al. In vitro susceptibility to TRAIL-induced apoptosis of acute leukemia cells in the context of TRAIL receptor gene expression and constitutive NF-κB activity. Leukemia 2001; 15: 921-928.
60. Baumgartner B, Weber M, Quirling M, Fischer C, Page S, Adam M et al. Increased IkappaB kinase activity is associated with activated NF-κB in acute myeloid blasts. Leukemia 2002; 16: 2062-2071.
61. Guzman ML, Swiderski CF, Howard DS, Grimes BA, Rossi RM, Szilvassy SJ et al. Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci USA 2002; 99: 16220-16225.
62. Romano MF, Petrella A, Bisogni R, Turco MC, Venuta S. Effect of NF-κB/Rel inhibition on spontaneous vs chemotherapy-induced apoptosis in AML and normal cord blood CD34+cells. Leukemia 2003; 17: 1190-1192.
63. Romano MF, Lamberti A, Tassone P, Alfinito F, Costantini S, Chiurazzi F et al. Triggering of CD40 antigen inhibits fludarabine-induced apoptosis in B chronic lymphocytic leukemia cells. Blood 1998; 92: 990-995.
64. Romano MF, Lamberti A, Bisogni R, Garbi C, Pagnano AM, Auletta P et al. Amifostine inhibits hematopoietic progenitor cell apoptosis by activating NF-κB/Rel transcription factors. Blood 1999; 94: 4060-4066.
65. Kurreck J. Antisense technologies. Improvement through novel chemical modifications. Eur J Biochem 2003; 270: 1628-1644.
66. Zhou A, Scoggin S, Gaynor RB, Williams NS. Identification of NF-κB-regulated genes induced by TNFκ utilizing expression profiling and RNA interference. Oncogene 2003; 22: 2054-2064.
67. Adams J. Proteasome inhibition: a novel approach to cancer therapy. Trends Mol Med 2002; 8: S49-54.
68. Mattaj JW, Englmeier L. Nuclecytoplasmic transport: the soluble phase. Annu Rev Biochem 1998; 67: 265-306.
69. Gould C, Wong CF. Designing specific protein kinase inhibitors: insights from computer simulations and comparative sequence/structure analysis. Pharmacol Ther 2002; 93: 169-178.
70. Pyatt DW, Stillman WS, Yang Y, Gross S, Zheng JH, Irons RD. An essential role for NF-κB in human CD34(+) bone marrow cell survival. Blood 1999; 93: 3302-3308.
71. Besancon F, Atfi A, Gespach C, Cayre YE, Bourgeade MF. Evidence for a role of NF-κB in the survival of hematopoietic cells mediated by interleukin 3 and oncogenic TEL/platelet-derived growth factor receptor beta fusion protein. Proc Natl Acad Sci USA 1998; 95: 8081-8087.
72. del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 1997; 278: 687-689.
73. Zhu J, Emerson SG. Hematopoietic cytokines, transcription factors and lineage commitment. Oncogene 2002; 21: 3295-3313.
74. Webster GA, Perkins ND. Transcriptional cross talk between NF-κB and p53. Mol Cell Biol 1999; 19: 3485-3495.
75. Hinz M, Lemke P, Anagnostopoulos I, Hacker C, Krappmann D, Mathas S et al. Nuclear factor κB-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity. J Exp Med 2002; 196: 605-617.
76. Biswas DK, Martin KJ, McAlister C, Cruz AP, Graner E, Dai SC et al. Apoptosis caused by chemotherapeutic inhibition of nuclear factor-κB activation. Cancer Res 2003; 63: 290-295.
77. Rayet B, Fan Y, Gelinas C. Mutations in the v-Rel transactivation domain indicate altered phosphorylation and identify a subset of NF-κB-regulated cell death inhibitors important for v-Rel transforming activity. Mol Cell Biol 2003; 23: 1520-1533.
78. Richter BW, Duckett CS. The IAP proteins: caspase inhibitors and beyond. Sci STKE 2000; 44: PE1.
79. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003; 3: 46-54.
80. Fukuda S, Pelus LM. Regulation of the inhibitor-of-apoptosis family member survivin in normal cord blood and bone marrow CD34(+) cells by hematopoietic growth factors: implication of survivin expression in normal hematopoiesis. Blood 2001; 98: 2091-2100.
81. Fukuda S, Pelus LM. Elevation of survivin levels by hematopoietic growth factors occurs in quiescent CD34+ hematopoietic stem and progenitor cells before cell cycle entry. Cell Cycle 2002; 1: 322-326.
82. Fukuda S, Foster RG, Porter SB, Pelus LM. The antiapoptosis protein survivin is associated with cell cycle entry of normal cord blood CD34(+) cells and modulates cell cycle and proliferation of mouse hematopoietic progenitor cells. Blood 2002; 100: 2463-2471.
83. Holcik M, Sonenberg N, Korneluk RG. Internal ribosome initiation of translation and the control of cell death. Trends Genet 2000; 16: 469-473.
84. Micheau O, Lens S, Gaide O, Alevizopoulos K, Tschopp J. NF-κB signals induce the expression of c-FLIP. Mol Cell Biol 2001; 21: 5299-5305.
85. Bentires-Alj M, Barbu V, Fillet M, Chariot A, Relic B, Jacobs N et al. NF-κB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene 2003; 22: 90-97.
86. Wang CY, Guttridge DC, Mayo MW, Baldwin Jr AS. NF-κB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol 1999; 19: 5923-5929.
87. Zong WX, Edelstein LC, Chen C, Bash J, Gelinas C. The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-κB that blocks TNFalpha-induced apoptosis. Genes Dev 1999; 13: 382-387.
88. Jones PL, Ping D, Boss JM. Tumor necrosis factor alpha and interleukin-1beta regulate the murine manganese superoxide dismutase gene through a complex intronic enhancer involving C/EBP-beta and NF-κB. Mol Cell Biol 1997; 17: 6970-6981.
89. Heyninck K, De Valck D, Vanden Berghe W, Van Criekinge W, Contreras R, Fiers W et al. The zinc finger protein A20 inhibits TNF-induced NF-κB-dependent gene expression by interfering with an RIP- or TRAF2-mediated transactivation signal and directly binds to a novel NF-κB-inhibiting protein ABIN. J Cell Biol 1999; 145: 1471-1482.
90. He KL, Ting AT. A20 inhibits tumor necrosis factor (TNF) alpha-induced apoptosis by disrupting recruitment of TRADD and RIP to the TNF receptor 1 complex in Jurkat T cells. Mol Cell Biol 2002; 22: 26034-26045.
91. Tran H, Brunet A, Griffith EC, Greenberg ME. The many forks in FOXO's road. Sci STKE 2003; 172: RE5.
92. Nozaki S, Sledge Jr GW, Nakshatri H. Repression of GADD153/CHOP by NF-κB: a possible cellular defense against endoplasmic reticulum stress-induced cell death. Oncogene 2001; 20: 2178-2185.
93. Mollace V, Nottet HS, Clayette P, Turco MC, Muscoli C, Salvemini D et al. Oxidative stress and neuroAIDS: triggers, modulators and novel antioxidants. Trends Neurosci 2001; 24: 411-416.
94. Akiyama M, Hideshima T, Hayashi T, Tai YT, Mitsiades CS, Mitsiades N et al. Nuclear factor-κB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein. Cancer Res 2003; 63: 18-21.
95. Ni H, Ergin M, Huang Q, Qin JZ, Amin HM, Martinez RL et al. Analysis of expression of nuclear factor kappa B (NF-κB) in multiple myeloma: downregulation of NF-kappa B induces apoptosis. Br J Haematol 2001; 115: 279-286.
96. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T et al. Biologic sequelae of nuclear factor-κB blockade in multiple myeloma: therapeutic applications. Blood 2002; 99: 4079-4086.
97. Parker KM, Ma MH, Manyak S, Altamirano CV, Tang YM, Frantzen M et al. Identification of polymorphisms of the IκBκ gene associated with an increased risk of multiple myeloma. Cancer Genet Cytogenet 2002; 137: 43-48.
98. Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D et al. Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene 2002; 21: 5673-5683.
99. Feinman R, Koury J, Thames M, Barlogie B, Epstein J, Siegel DS. Role of NF-κB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2. Blood 1999; 93: 3044-3052.
100. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002; 99: 4525-4530.
101. Mitsiades CS, Treon SP, Mitsiades N, Shima Y, Richardson P, Schlossman R et al. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 2001; 98: 795-804.
102. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T et al. NF-κB as a therapeutic target in multiple myeloma. J Biol Chem 2002; 277: 16639-16647.
103. Testorelli C. Telomerase and cancer. J Exp Clin Cancer Res 2003; 22: 165-169.
104. Darnell Jr JE. Transcription factors as targets for cancer therapy. Nat Rev Cancer 2002; 2: 740-749.